The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.
Henning Schulze-Bergkamen
No relevant relationships to disclose
Dirk Jaeger
No relevant relationships to disclose
Hans-Georg Kopp
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Michael Bitzer
Honoraria - 4SC AG
Anna Mais
Employment or Leadership Position - 4SC AG
Karin Resemann
Employment or Leadership Position - 4SC AG
Bernhard Hauns
Employment or Leadership Position - 4SC AG
Julia Asche
Employment or Leadership Position - 4SC AG
Stefan W. Henning
Employment or Leadership Position - 4SC AG
Stock Ownership - 4SC AG
Bernd Hentsch
Employment or Leadership Position - 4SC AG
Stock Ownership - 4SC AG